Indications
Myfenax is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Composition
- Active substance
- mycophenolate mofetil
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Myfenax
- Active substance
- mycophenolate mofetil
- ATC code
- L04AA06
- Therapeutic area
- Graft Rejection
- Marketing authorisation holder
- Teva B.V.
- Status
- Authorised